Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518163 | 0.68 | SLC9A1 (0.48) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL628179 | 0.68 | SLC9A1 (0.48) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL11959496 | 0.66 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL15548600 | 0.66 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL11044976 | 0.66 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL11872036 | 0.66 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL367850 | 0.66 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL3072391 | 0.65 | SLC9A1 (0.60) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL9697480 | 0.62 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM | |
| SCHEMBL3745056 | 0.62 | SLC9A1 (0.56) | SLC9A1MAPTPOLBMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396846-B2 | Growth hormone secretagogues | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7285662-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| EP-1497317-B1 | DIPEPTIDIC GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060178372-A1 | Therapeutic quinoline compounds | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | US | disclosed |
| US-20060167268-A1 | Growth hormone secretagogues | ELI LILLY AND COMPANY, PATENT DIVISION, (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1497316-B1 | GROWTH HORMONE SECRETAGOGUES | LILLY CO ELI (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20060135554-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| US-7045514-B2 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-7030139-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-04-18 | — | — | US | disclosed |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | PIERSON EDWARD (US) | 2005-01-13 | — | — | US | disclosed |
| US-6812225-B2 | PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | ASTRAZENECA AB (SE) | 2004-11-02 | — | — | US | disclosed |
| EP-1451158-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20040116465-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20040110745-A1 | Therapeutic chroman compounds | INTEL CORPORATION | 2004-06-10 | — | — | US | disclosed |
| US-20040087575-A1 | Therapeutic chromone compounds | SPORT COURT INTERNATIONAL, INC. | 2004-05-06 | — | — | US | disclosed |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | disclosed |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| WO-2003037872-A1 | THERAPEUTIC QUINOLINE COMPOUNDS WITH 5-HT-ANTAGONISTIC PROPERTIES | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076759-A1 | Therapeutic Heterocyclic Compounds 507 | HTR1A, HTR1B, HTR1D | SLC9A1 1166/4885MAPT 698/4885POLB 3300/4885 |
| US-20060178372-A1 | Therapeutic quinoline compounds | HTR1B, HTR3B, HTR1A | SLC9A1 736/4885MAPT 628/4885POLB 2260/4885 |
| US-20040087575-A1 | Therapeutic chromone compounds | HTR1B, HTR1A, HTR3B | SLC9A1 1860/4885MAPT 941/4885POLB 2691/4885 |
| US-20050009818-A1 | Therapeutic heterocyclic compounds | HTR1B, HTR1D, HTR1A | SLC9A1 875/4885MAPT 653/4885POLB 3401/4885 |
| US-20060135554-A1 | Novel compounds | OPRL1, OPRK1, TRPV1 | SLC9A1 2190/4885MAPT 3276/4885POLB 3819/4885 |
| US-20030013708-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | SLC9A1 782/4885MAPT 661/4885POLB 3472/4885 |
| US-20040082591-A1 | Therapeutic heterocyclic compounds | HTR1A, HTR1D, HTR1B | SLC9A1 837/4885MAPT 637/4885POLB 3369/4885 |
| US-20040110745-A1 | Therapeutic chroman compounds | HTR1A, ACHE, CALCA | SLC9A1 2043/4885MAPT 1085/4885POLB 4031/4885 |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | SLC9A1 3309/4885MAPT 4848/4885POLB 1848/4885 |
| US-20060167268-A1 | Growth hormone secretagogues | GHSR, GHRHR, CRH | SLC9A1 4249/4885MAPT 4706/4885POLB 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.